Navigation Links
WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
Date:12/2/2011

LOS ANGELES, December 2, 2011 /PRNewswire/ -- WestPark Capital, Inc. announced the completion of a public offering for IsoRay, Inc. (NYSE Amex: ISR). A total of 2,817,988 shares of common stock and warrants to purchase up to 563,598 shares of common stock were sold, generating gross proceeds of $2,592,549 in the offering. Proceeds from the offering will be used to fund new applications for IsoRay's Cesium-131 technology to treat lung, head and neck, breast and brain cancers, and for working capital and general corporate purposes. WestPark Capital, Inc. acted as lead manager for the offering. This offering was originated through Tekesta Capital Partners, a division of WestPark Capital, Inc.

This press release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The offering was made only by prospectus. A prospectus supplement relating to the common stock and warrants issued in the offering has been declared effective by the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained at the SEC website at www.sec.gov, or via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

About WestPark Capital, Inc.

WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them.  WestPark provides a comprehensive range of corporate finance services, including initial public offerings, reverse mergers, follow-on offerings, private placements and corporate finance advisory services. Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at info@wpcapital.com.

About IsoRay, Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the exclusive producer of Cesium-131 internal radiation therapy, which is expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.

Contact:

WestPark Capital, Inc.
Richard Rappaport, CEO
310) 843-9300


'/>"/>
SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WestPark Capital Announces $2.6 Million IsoRay Offering
2. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
3. Concord Medical Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting, Board and Management Changes
4. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
5. Walmart Announces Generic Lipitor® (Atorvastatin Calcium Tablets) Available in Stores Today
6. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
7. Arbor Pharmaceuticals Announces Filing of First NDA
8. HASCO Medical Announces Approval to Acquire Certified Medical and Certified Auto of Ocala
9. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
10. Forbes Announces IntegriChain in Top 20 on List of Americas Most Promising Companies
11. Kewaunee Scientific Announces Results for Second Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... Three Tru-D SmartUVC robots have arrived at Brian ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing ... services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army ... "Although the BAACH has a very low infection ...
(Date:7/27/2017)... Ind., July 27, 2017  Zimmer Biomet Holdings, Inc. ... quarter ended June 30, 2017.  The Company reported second ... 1.1% over the prior year period, and an increase ... 240 basis points of contribution from the LDR Holding ... the second quarter of 2016, or 0.3% on a ...
(Date:7/26/2017)... 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) today ... evaluating Altemia TM , an oral therapy for pediatric ... Disease (SCD). The SCOT Trial, is a double-blind, placebo-controlled, ... of Altemia TM in pediatric patients aged 5-17 ... 125274. "The completion ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... ... of “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... protection services and financial consultations to communities throughout the greater DC region, is ... with the goal of rescuing local animals and training them to be companions ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an Indiana-based firm ... in support of Campagna Academy in a charity drive to provide for at-risk children ... of Indiana,” Campagna Academy is a nonprofit organization that has offered critical programs to ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... highly trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has ... imbalance and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, ... and monitoring solutions, announced today the launch of a redesigned corporate website, ... and aesthetic, fully responsive design, and an enhanced search directory for businesses and ...
Breaking Medicine News(10 mins):